Third Rock Raises $1.1B Fund, Sticks With Its Knitting in a Downturn

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

MOMA Gets $150M to Make Small Molecules Against ATPases, Laborers of the Cell
Third Rock-Backed Abata Secures $95M for T-reg Cell Therapy Against MS
Third Rock and Friends Bet $110M On Thrive, a Hopkins-Inspired Cancer Screening Startup
Betting on Biotech IPOs? What If You Buy the Third Rock and ARCH Portfolios?